Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $107.9100 (0.95%) ($107.1400 - $108.5500) on Fri. Apr. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 1.56% (three month average) | RSI | 58 | Latest Price | $107.9100(0.95%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ABBV advances 0.1% a day on average for past five trading days. | Weekly Trend | ABBV advances 0.1% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(45%) SPLV(36%) XLP(33%) VYM(32%) DIA(31%) | Factors Impacting ABBV price | ABBV will decline at least -0.78% in a week (0% probabilities). VIXM(-21%) UUP(-10%) VXX(-3%) IGOV(-3%) TLT(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.78% (StdDev 1.56%) | Hourly BBV | 1.1 () | Intraday Trend | 0.4% | | | |
|
5 Day Moving Average | $107.43(0.45%) | 10 Day Moving Average | $106.79(1.05%) | 20 Day Moving Average | $106.31(1.51%) | To recent high | -4.2% | To recent low | 5.5% | Market Cap | $190.384b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |